propafenone has been researched along with Tachycardia, Paroxysmal in 38 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Tachycardia, Paroxysmal: Abnormally rapid heartbeats with sudden onset and cessation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 9.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 9.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 9.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 8.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "Propafenone was clinically effective (complete relief of symptoms) in 26 (74%) patients." | 6.68 | The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. ( Ceremuzynski, L; Czepiel, A; Karczmarewicz, S; Karpinski, G; Kulakowski, P; Makowska, E; Wolk, R, 1996) |
| "Propafenone was given to 60 children (mean age 4." | 5.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 5.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 5.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "To evaluate the electrophysiological effects of intravenous propafenone in the anterograde and retrograde effective refractory period of the accessory pathways (AP), in patients with Wolff-Parkinson-White syndrome." | 5.07 | [Acute effects of propafenone in patients with ventricular pre-excitation]. ( Cruz Filho, F; Fagundes, ML; Lorga, AM; Loyola, LH; Maia, IG; Pimenta, J, 1993) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 5.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 4.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| ") and oral propafenone were evaluated in 14 patients with Wolff-Parkinson-White syndrome and in 10 patients with atrioventricular (AV) nodal reentrant tachycardia." | 3.67 | Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. ( Lüderitz, B; Manz, M; Steinbeck, G, 1985) |
| "Propafenone was clinically effective (complete relief of symptoms) in 26 (74%) patients." | 2.68 | The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. ( Ceremuzynski, L; Czepiel, A; Karczmarewicz, S; Karpinski, G; Kulakowski, P; Makowska, E; Wolk, R, 1996) |
| "The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0." | 2.67 | Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. ( McCarthy, EA; Pritchett, EL; Wilkinson, WE, 1991) |
| " With the intravenous administration of the drug in a dosage of 1." | 2.65 | [Propafenon therapy of arrhythmias in infancy and childhood (author's transl)]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1981) |
| "Propafenone was given to 60 children (mean age 4." | 1.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "Propafenone was administered to 32 patients, with positive results in 15 (46." | 1.28 | Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing. ( Bertoldi, A; Dallago, M; Del Greco, M; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1992) |
| "Propafenone was tested in 13 patients (43." | 1.28 | [Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?]. ( Braito, G; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1991) |
| "Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6." | 1.28 | [Use of propafenone in emergency therapy]. ( Di Ieso, N; Guardascione, A; Liguori, A; Pellegrino, G; Piatto, A; Ruggiero, P; Scarnera, P, 1989) |
| " In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day." | 1.28 | Paroxysmal supraventricular tachycardia: experience with propafenone. ( Chiariello, M; De Paola, M; Santinelli, V; Smimmo, D; Turco, P, 1989) |
| " Propafenone controlled dysrhythmia very well in 4 out of the ten patients, and satisfactorily in another one at a dosage ranging from 450 to 900 mg/day in 3 or 4 divided doses; this result was documented using continuous 24 hr." | 1.28 | [Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents]. ( Amiel, A; Boutaud, P; Ciber, M; Demange, J; Guillem, JP; Herpin, D; Maarek-Charbit, M, 1989) |
| "Propafenone was administered during electrophysiologic testing to determine its efficacy and safety for terminating and preventing reinduction of paroxysmal supraventricular reentrant tachycardia." | 1.27 | Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. ( Gersh, BJ; Hammill, SC; Holmes, DR; McLaran, CJ; Osborn, MJ; Wood, DL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (39.47) | 18.7374 |
| 1990's | 19 (50.00) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chachua, T | 1 |
| Abuladze, G | 1 |
| Nebieridze, M | 1 |
| van Stuijvenberg, M | 1 |
| Beaufort-Krol, GC | 1 |
| Haaksma, J | 1 |
| Bink-Boelkens, MT | 1 |
| Liu, X | 3 |
| Long, D | 1 |
| Dong, J | 1 |
| Hu, F | 1 |
| Yu, R | 1 |
| Tang, R | 1 |
| Fang, D | 1 |
| Hao, P | 1 |
| Lu, C | 1 |
| He, X | 1 |
| Ma, C | 1 |
| Koshumbaeva, KM | 1 |
| Belokopit, IN | 1 |
| Makhanov, DI | 1 |
| Nugmanova, MN | 1 |
| Weber, H | 1 |
| Eigster, G | 1 |
| Wesselhoeft, H | 1 |
| Garcia-Civera, R | 1 |
| Sanjuan, R | 1 |
| Morell, S | 1 |
| Ferrero, JA | 1 |
| Miralles, L | 1 |
| Llavador, J | 1 |
| Lopez-Merino, V | 1 |
| Furlanello, F | 3 |
| Vergara, G | 3 |
| Dal Forno, P | 1 |
| Disertori, M | 1 |
| Inama, G | 3 |
| Ruipérez Abizanda, JA | 1 |
| Campos Peris, JV | 1 |
| Ruiz Ros, JA | 1 |
| García García, J | 1 |
| Jaen Armand, E | 1 |
| Marco Quiles, J | 1 |
| Martínez Jerez, M | 1 |
| Salas Nieto, J | 1 |
| Rodríguez Ruiz, P | 1 |
| Pico Aracil, F | 1 |
| Waleffe, A | 1 |
| Mary-Rabine, L | 1 |
| de Rijbel, R | 1 |
| Soyeur, D | 1 |
| Legrand, V | 1 |
| Kulbertus, HE | 1 |
| Marafioti, V | 1 |
| Carbonieri, E | 1 |
| Zardini, P | 1 |
| Santinelli, V | 3 |
| Arnese, M | 1 |
| Oppo, I | 1 |
| Matarazzi, C | 1 |
| Maione, S | 1 |
| Palma, M | 1 |
| Giunta, A | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 2 |
| Lüderitz, B | 2 |
| Maia, IG | 1 |
| Cruz Filho, F | 1 |
| Fagundes, ML | 1 |
| Loyola, LH | 1 |
| Pimenta, J | 1 |
| Lorga, AM | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Vignati, G | 1 |
| Mauri, L | 1 |
| Figini, A | 1 |
| Telichowski, A | 2 |
| Banasiak, W | 2 |
| Ponikowski, P | 1 |
| Wiech, K | 2 |
| Zebrowski, J | 2 |
| Pieróg, M | 2 |
| Kałka, D | 1 |
| Lacheta, W | 2 |
| Fuglewicz, A | 1 |
| Molenda, W | 1 |
| Chimienti, M | 1 |
| Cullen, MT | 1 |
| Casadei, G | 1 |
| Wolk, R | 1 |
| Kulakowski, P | 1 |
| Karczmarewicz, S | 1 |
| Karpinski, G | 1 |
| Makowska, E | 1 |
| Czepiel, A | 1 |
| Ceremuzynski, L | 1 |
| Kokot, K | 1 |
| Zapałowicz, R | 1 |
| Telichowski, C | 1 |
| Mirone, L | 1 |
| Altomonte, L | 1 |
| Ferlisi, EM | 1 |
| Zoli, A | 1 |
| Magaró, M | 1 |
| Gómez-Barrado, JJ | 1 |
| García-Rubira, JC | 1 |
| Turégano Albarrán, S | 1 |
| Pavón García, M | 1 |
| Hidalgo Urbano, R | 1 |
| Montes Ramírez, JM | 1 |
| Cruz Fernández, JM | 1 |
| Rae, AP | 1 |
| Guarnerio, M | 2 |
| Del Greco, M | 1 |
| Bertoldi, A | 1 |
| Dallago, M | 1 |
| Braito, G | 1 |
| Pritchett, EL | 1 |
| McCarthy, EA | 1 |
| Wilkinson, WE | 1 |
| Turco, P | 2 |
| De Paola, M | 2 |
| Smimmo, D | 2 |
| Giasi, M | 1 |
| Santinelli, C | 1 |
| Chiariello, M | 2 |
| Condorelli, M | 1 |
| Liguori, A | 1 |
| Pellegrino, G | 1 |
| Di Ieso, N | 1 |
| Piatto, A | 1 |
| Ruggiero, P | 1 |
| Scarnera, P | 1 |
| Guardascione, A | 1 |
| Boutaud, P | 1 |
| Guillem, JP | 1 |
| Maarek-Charbit, M | 1 |
| Amiel, A | 1 |
| Ciber, M | 1 |
| Herpin, D | 1 |
| Demange, J | 1 |
| Musto, B | 2 |
| D'Onofrio, A | 2 |
| Cavallaro, C | 2 |
| Musto, A | 2 |
| Lee, PK | 1 |
| Kerr, CR | 1 |
| Vorderbrugge, S | 1 |
| Qi, AZ | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Hammill, SC | 1 |
| McLaran, CJ | 1 |
| Wood, DL | 1 |
| Osborn, MJ | 1 |
| Gersh, BJ | 1 |
| Holmes, DR | 1 |
| Marsico, F | 1 |
| Kasanuki, H | 1 |
| Onishi, S | 1 |
| Hirosawa, K | 1 |
| Steinbeck, G | 1 |
| Arboix, M | 1 |
| Puigdemont, A | 1 |
| Moya, A | 1 |
| Cinca, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.[NCT02614521] | 0 participants (Actual) | Observational | 2017-01-31 | Withdrawn | |||
| [NCT00005237] | 0 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for propafenone and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Controlled Clinic | 1998 |
11 trials available for propafenone and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
Is circumferential pulmonary vein isolation preferable to stepwise segmental pulmonary vein isolation for patients with paroxysmal atrial fibrillation?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ab | 2006 |
[Propafenon therapy of arrhythmias in infancy and childhood (author's transl)].
Topics: Adolescent; Age Factors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Atrioventricu | 1981 |
[Propafenone, a new anti arrhythmic agent].
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Clinical Trials as Topic; Drug Evaluation; Female; Human | 1980 |
A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle A | 1995 |
Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.
Topics: Adolescent; Adult; Blood Pressure; Echocardiography; Female; Flecainide; Heart Rate; Humans; Male; M | 1993 |
[Acute effects of propafenone in patients with ventricular pre-excitation].
Topics: Adolescent; Adult; Atrioventricular Node; Electrocardiography; Female; Heart Block; Humans; Male; Mi | 1993 |
[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Electrocar | 1995 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, Ambulatory; Evaluation Studi | 1996 |
Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follo | 1991 |
Propafenone in Wolff-Parkinson-White syndrome at risk.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Fema | 1990 |
24 other studies available for propafenone and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
[The efficacy of propafenon in the case of supraventricular atrioventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Drug Evaluation; Female; Humans; Male; Propafenone; Tachycardia, Paroxysmal; | 2010 |
Pharmacological treatment of young children with permanent junctional reciprocating tachycardia.
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infan | 2003 |
[Preventive efficacy of propafenone, its effect on functional state of the heart during long-term treatment of patients with paroxysmal atrioventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Hea | 2006 |
Effects of propafenone on induction and maintenance of atrioventricular nodal reentrant tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardi | 1984 |
[Clinical experience with propafenone in paroxysmal supraventricular reciprocating tachycardias].
Topics: Anti-Arrhythmia Agents; Drug Evaluation; Female; Heart Rate; Humans; Male; Propafenone; Propiophenon | 1984 |
Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electric Stimulation; Female; Heart; Hear | 1981 |
Cases in electrocardiography.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Propafenone; Tachycardia, Par | 1995 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
The use of propafenone in the treatment of tachyarrhythmias in children.
Topics: Administration, Oral; Child, Preschool; Electrocardiography; Female; Humans; Injections, Intravenous | 1993 |
[Effect of intravenous propafenone on maintenance of atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Injections, Intravenous; Male; Mi | 1996 |
Behçet's disease and cardiac arrhythmia.
Topics: Adolescent; Anti-Arrhythmia Agents; Behcet Syndrome; Echocardiography, Doppler; Electrocardiography; | 1997 |
[Circulatory arrest after combined intravenous drugs for the treatment of orthodromic circular tachycardia of Wolff-Parkinson-White syndrome].
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Female; Heart Arrest; Humans; Middle | 1997 |
Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing.
Topics: Adult; Cardiac Pacing, Artificial; Female; Flecainide; Follow-Up Studies; Humans; Male; Propafenone; | 1992 |
[Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?].
Topics: Adolescent; Adult; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography; Female; Flecain | 1991 |
[Use of propafenone in emergency therapy].
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiograp | 1989 |
Paroxysmal supraventricular tachycardia: experience with propafenone.
Topics: Administration, Oral; Adult; Electrophysiology; Female; Humans; Infusions, Intravenous; Male; Middle | 1989 |
[Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].
Topics: Administration, Oral; Aged; Disopyramide; Drug Evaluation; Drug Resistance; Female; Humans; Male; Mi | 1989 |
Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia.
Topics: Cardiac Pacing, Artificial; Child; Electrocardiography; Electrophysiology; Female; Follow-Up Studies | 1988 |
Symptomatic sinus node dysfunction associated with the use of propafenone.
Topics: Bradycardia; Cardiac Pacing, Artificial; Heart Diseases; Humans; Propafenone; Sinoatrial Node; Synco | 1988 |
Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
Topics: Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Conduction System; Hemodynamics; | 1987 |
[Electrophysiologic effects and clinical efficacy of propafenone in pediatric patients with paroxysmal supraventricular reentrant tachycardia].
Topics: Adolescent; Anti-Arrhythmia Agents; Child; Child, Preschool; Electrocardiography; Female; Heart Cond | 1986 |
The usefulness of electrophysiological-pharmacologic studies in the long-term therapy of paroxysmal tachycardias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chromatogra | 1985 |
Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Child; | 1985 |
Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.
Topics: Adult; Electrophysiology; Female; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Middle | 1985 |